TrialBMC neurology2017

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.

Douglas L Arnold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.